9 results
Investigate the value of percutaneous radiofrequency heat lesion applied to the ramus communicans; more specifically try to determine if a significant and long lasting pain reduction can be obtained as compared to a sham-operated group. In addition…
Investigate the value of percutaneous radiofrequency heat lesion, applied to the medial branch of the primary dorsal ramus; more specifically try to determine if a significant and long lasting pain reduction can be obtained as compared to a sham-…
investigate the value of percutaneous pulsed radiofrequency, applied to the lumbar and sacral dorsal root ganglion; more specifically try to determine if a significant and long lasting pain reduction can be obtained as compared to a sham-operated…
The aim of this study is to determine whether LNP023 is effective and safe for the treatment of PNH. LNP023 is compared to the Standard of Care (SOC) anti-C5 antibody treatment. The primary objectives are to:• Demonstrate superiority of LNP023…
The primary objective is to evaluate the long-term safety and tolerability of iptacopan in eligible participants. The primary clinical question of interest is: what is the long-term safety and tolerability of iptacopan in IgAN participants including…
Participants enrolling from study CLNP023B12301 or CLNP023B12302• Primary Objective: To evaluate the long-term safety and tolerability of iptacopan in participants with C3G or IC-MPGN
Primary objective adults:To demonstrate the superiority of iptacopan (200 mg b.i.d.) compared to placebo in reducing proteinuria at 6 months of treatment.The primary clinical question of interest is:What is the effect of iptacopan vs. placebo on log…
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of iptacopan in patients with PNH and to provide access to patients who have completed the treatment extension period (without tapering down) of the Phase 2…
The purpose of the study is to evaluate the efficacy and safety of LNP023 compared to placebo on proteinuria reduction and slowing renal disease progression in primary IgAN patients